| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| ANVSAnnovis Bio, Inc. | 84.81M | 3.20 | -0.00 | -189.15% | ||||
| CLNNClene Inc. | 60.19M | 5.11 | -0.90 | -47.71% | -142.5% | -17.38% | ||
| ABOSAcumen Pharmaceuticals, Inc. | 112.67M | 1.86 | -1.09 | -143.12% | 0.16 | |||
| BHVNBiohaven Ltd. | 1.58B | 11.92 | -1.28 | -198.83% | 0.09 | |||
| IKTInhibikase Therapeutics, Inc. | 200.09M | 1.65 | -1.42 | -100% | -65.37% | 0.00 | ||
| ALECAlector, Inc. | 198.66M | 1.82 | -1.48 | 3.6% | -156.03% | -186.68% | 0.34 | |
| CGTXCognition Therapeutics, Inc. | 121.82M | 1.38 | -1.62 | -76.61% | 0.04 | |||
| ATHEAlterity Therapeutics Limited | 60M | 3.31 | -2.90 | 35.32% | -330.63% | -73.75% | 0.00 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 15.58M | 1.8M | 311K | 0 | 6.83M | 32.17M | 18.44M | 9.43M | 0 | 0 |
| Revenue Growth % | -0.45% | -0.88% | -0.83% | -1% | - | 3.71% | -0.43% | -0.49% | -1% | - |
| Cost of Goods Sold | 2.76M | 1.11M | 25.57M | 6M | 0 | 0 | 0 | 0 | 167.51M | 2.56M |
| COGS % of Revenue | 0.18% | 0.62% | 82.23% | - | - | - | - | - | - | - |
| Gross Profit | 12.81M | 689K | -25.26M | -6M | 6.83M | 32.17M | 18.44M | 9.43M | -167.51M | -2.56M |
| Gross Margin % | 0.82% | 0.38% | -81.23% | - | 1% | 1% | 1% | 1% | - | - |
| Gross Profit Growth % | -0.43% | -0.95% | -37.66% | 0.76% | 2.14% | 3.71% | -0.43% | -0.49% | -18.76% | 0.98% |
| Operating Expenses | 24.94M | 26.62M | 32.89M | 32.02M | 49.65M | 63.47M | 97.43M | 138.58M | 46.54M | 276.74M |
| OpEx % of Revenue | 1.6% | 14.76% | 105.74% | - | 7.27% | 1.97% | 5.28% | 14.69% | - | - |
| Selling, General & Admin | 9.79M | 6.79M | 7.31M | 8.38M | 10.8M | 12.94M | 21.97M | 32.81M | 46.54M | 68.9M |
| SG&A % of Revenue | 0.63% | 3.77% | 23.51% | - | 1.58% | 0.4% | 1.19% | 3.48% | - | - |
| Research & Development | 15.15M | 19.83M | 25.57M | 23.63M | 38.84M | 50.52M | 75.46M | 105.77M | 167.51M | 210.39M |
| R&D % of Revenue | 0.97% | 11% | 82.23% | - | 5.69% | 1.57% | 4.09% | 11.21% | - | - |
| Other Operating Expenses | -6.39M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -167.51M | -2.56M |
| Operating Income | -9.36M | -24.82M | -32.58M | -38.02M | -42.82M | -31.3M | -78.99M | -129.14M | -214.05M | -279.3M |
| Operating Margin % | -0.6% | -13.76% | -104.74% | - | -6.27% | -0.97% | -4.28% | -13.69% | - | - |
| Operating Income Growth % | -1.84% | -1.65% | -0.31% | -0.17% | -0.13% | 0.27% | -1.52% | -0.63% | -0.66% | -0.3% |
| EBITDA | -8.32M | -23.95M | -31.93M | -37.43M | -42.39M | -30.66M | -78.09M | -127.74M | -210.51M | -276.74M |
| EBITDA Margin % | -0.53% | -13.29% | -102.66% | - | -6.21% | -0.95% | -4.24% | -13.54% | - | - |
| EBITDA Growth % | -1.7% | -1.88% | -0.33% | -0.17% | -0.13% | 0.28% | -1.55% | -0.64% | -0.65% | -0.31% |
| D&A (Non-Cash Add-back) | 1.04M | 864K | 649K | 586K | 429K | 644K | 906K | 1.41M | 3.54M | 2.56M |
| EBIT | -9.36M | -24.82M | -30.7M | -33.13M | -40.18M | -28.61M | -78.99M | -129.14M | -214.05M | -238.42M |
| Net Interest Income | 542K | 504K | 477K | -178K | 919K | 1.79M | 466K | 8.71M | 27.62M | 41.94M |
| Interest Income | 542K | 504K | 477K | 1.22M | 2.35M | 2.28M | 466K | 8.71M | 27.62M | 41.94M |
| Interest Expense | 0 | 0 | 0 | 1.39M | 1.43M | 484K | 0 | 0 | 0 | 0 |
| Other Income/Expense | -6.39M | 1.82M | 1.87M | 6.4M | 1.2M | 2.21M | 105K | 3.89M | 31.37M | 40.88M |
| Pretax Income | -15.75M | -23M | -30.7M | -34.5M | -41.62M | -29.09M | -78.89M | -125.25M | -182.69M | -238.42M |
| Pretax Margin % | -1.01% | -12.75% | -98.73% | - | -6.09% | -0.9% | -4.28% | -13.28% | - | - |
| Income Tax | 0 | 0 | 0 | 4.91M | -23K | -257K | -6K | 118K | -292K | -4.09M |
| Effective Tax Rate % | 1% | 1% | 1% | 1% | 1% | 0.99% | 1% | 1% | 1% | 0.98% |
| Net Income | -15.75M | -23M | -30.7M | -34.5M | -41.59M | -28.84M | -78.88M | -125.37M | -182.39M | -234.33M |
| Net Margin % | -1.01% | -12.75% | -98.73% | - | -6.09% | -0.9% | -4.28% | -13.29% | - | - |
| Net Income Growth % | -2.21% | -0.46% | -0.34% | -0.12% | -0.21% | 0.31% | -1.74% | -0.59% | -0.45% | -0.28% |
| Net Income (Continuing) | -15.75M | -23M | -30.7M | -34.5M | -41.59M | -28.84M | -78.88M | -125.37M | -182.39M | -234.33M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.10 | -1.48 | -1.71 | -1.78 | -1.54 | -0.83 | -1.77 | -2.06 | -2.73 | -3.01 |
| EPS Growth % | -2.17% | -0.35% | -0.16% | -0.04% | 0.13% | 0.46% | -1.13% | -0.16% | -0.33% | -0.1% |
| EPS (Basic) | -1.10 | -1.48 | -1.71 | -1.78 | -1.54 | -0.83 | -1.77 | -2.06 | -2.73 | -3.01 |
| Diluted Shares Outstanding | 14.28M | 15.49M | 18M | 19.43M | 25.94M | 34.54M | 43.63M | 60.54M | 66.89M | 77.89M |
| Basic Shares Outstanding | 14.28M | 15.49M | 17.99M | 19.43M | 25.94M | 34.54M | 43.63M | 60.54M | 66.89M | 77.89M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 60.87M | 65.67M | 44.82M | 121.44M | 144.87M | 181.78M | 559.02M | 600.3M | 644.96M | 635.26M |
| Cash & Short-Term Investments | 58.65M | 64.15M | 43.67M | 119.31M | 141.36M | 177M | 551.77M | 592.09M | 638.08M | 626.9M |
| Cash Only | 58.65M | 17.09M | 20.49M | 67.75M | 24.75M | 45.01M | 175.69M | 57.24M | 148.64M | 142.71M |
| Short-Term Investments | 0 | 47.05M | 23.18M | 51.55M | 116.6M | 131.99M | 376.09M | 534.85M | 489.44M | 484.19M |
| Accounts Receivable | 315K | 200K | 438K | 151K | 813K | 1.82M | 2.77M | 986K | 874K | 1.47M |
| Days Sales Outstanding | 7.38 | 40.49 | 514.05 | - | 43.45 | 20.67 | 54.74 | 38.15 | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7.22M | 6.01M | 6.89M |
| Total Non-Current Assets | 3.08M | 1.81M | 1.3M | 991K | 2.83M | 7.4M | 12.99M | 153.85M | 319.84M | 162.88M |
| Property, Plant & Equipment | 1.99M | 1.4M | 1.07M | 991K | 2.59M | 6.88M | 12.52M | 16.91M | 18.85M | 18.22M |
| Fixed Asset Turnover | 7.83x | 1.28x | 0.29x | - | 2.63x | 4.68x | 1.47x | 0.56x | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 128.68M | 292.79M | 127.5M |
| Other Non-Current Assets | 1.09M | 408K | 230K | -105K | 0 | 0 | 0 | 7.75M | 7.4M | 7.5M |
| Total Assets | 63.95M | 67.49M | 46.12M | 122.43M | 147.7M | 189.19M | 572.01M | 754.15M | 964.8M | 798.14M |
| Asset Turnover | 0.24x | 0.03x | 0.01x | - | 0.05x | 0.17x | 0.03x | 0.01x | - | - |
| Asset Growth % | -0.27% | 0.06% | -0.32% | 1.65% | 0.21% | 0.28% | 2.02% | 0.32% | 0.28% | -0.17% |
| Total Current Liabilities | 2.78M | 3.52M | 4.08M | 4.12M | 43.38M | 14.78M | 14.32M | 22.7M | 27.27M | 35.59M |
| Accounts Payable | 1.09M | 1.46M | 1.25M | 665K | 2.47M | 3.04M | 3.82M | 8.49M | 8.6M | 5.07M |
| Days Payables Outstanding | 143.78 | 479.35 | 17.88 | 40.45 | - | - | - | - | 18.73 | 722.87 |
| Short-Term Debt | 0 | 0 | 700K | 0 | 4.65M | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 157K | 0 | 0 | -1000K | 1000K | 1000K | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 762K | 59K | 44K | 1.73M | 3.45M | 2.86M | 5.94M | 5.82M | 347K | 9.93M |
| Current Ratio | 21.88x | 18.68x | 10.98x | 29.48x | 3.34x | 12.30x | 39.03x | 26.44x | 23.65x | 17.85x |
| Quick Ratio | 21.88x | 18.68x | 10.98x | 29.48x | 3.34x | 12.30x | 39.03x | 26.44x | 23.65x | 17.85x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 133K | 70K | 6.1M | 15.01M | 12.34M | 3.05M | 7.65M | 9.95M | 9.6M | 7.65M |
| Long-Term Debt | 0 | 0 | 6.1M | 15.01M | 10.89M | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 743K | 3.05M | 7.65M | 9.95M | 9.6M | 7.65M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 10.89M | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 133K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 2.92M | 3.59M | 10.19M | 19.13M | 55.72M | 17.83M | 21.97M | 32.65M | 36.88M | 43.24M |
| Total Debt | 0 | 0 | 6.8M | 15.01M | 16.45M | 3.31M | 8.26M | 10.44M | 10.9M | 9.02M |
| Net Debt | -58.65M | -17.09M | -13.68M | -52.74M | -8.3M | -41.69M | -167.43M | -46.81M | -137.74M | -133.7M |
| Debt / Equity | - | - | 0.19x | 0.15x | 0.18x | 0.02x | 0.02x | 0.01x | 0.01x | 0.01x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest Coverage | - | - | - | -27.27x | -29.86x | -64.67x | - | - | - | - |
| Total Equity | 61.03M | 63.9M | 35.93M | 103.3M | 91.98M | 171.35M | 550.03M | 721.5M | 927.92M | 754.9M |
| Equity Growth % | -0.16% | 0.05% | -0.44% | 1.87% | -0.11% | 0.86% | 2.21% | 0.31% | 0.29% | -0.19% |
| Book Value per Share | 4.27 | 4.12 | 2.00 | 5.32 | 3.55 | 4.96 | 12.61 | 11.92 | 13.87 | 9.69 |
| Total Shareholders' Equity | 61.03M | 63.9M | 35.93M | 103.3M | 91.98M | 171.35M | 550.03M | 721.5M | 927.92M | 754.9M |
| Common Stock | 148.63M | 173.25M | 173.84M | 265.92M | 294.24M | 397.75M | 783.17M | 1.07B | 1.44B | 1.46B |
| Retained Earnings | -119.69M | -142.68M | -173.39M | -207.88M | -249.66M | -278.49M | -357.37M | -482.75M | -665.14M | -899.47M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -990K | -990K | -990K | -990K | -990K | -990K | -990K | -3M | -77K | -1.61M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -18.1M | -19.57M | -28.73M | -34.72M | -4.63M | -48.12M | -69.5M | -98.43M | -145.33M | -181.39M |
| Operating CF Margin % | -1.16% | -10.85% | -92.37% | - | -0.68% | -1.5% | -3.77% | -10.43% | - | - |
| Operating CF Growth % | -69.06% | -0.08% | -0.47% | -0.21% | 0.87% | -9.39% | -0.44% | -0.42% | -0.48% | -0.25% |
| Net Income | -15.75M | -23M | -30.7M | -34.5M | -41.59M | -28.84M | -78.88M | -125.37M | -182.39M | -234.33M |
| Depreciation & Amortization | 1.04M | 864K | 649K | 586K | 429K | 644K | 906K | 1.62M | 3.54M | 2.56M |
| Stock-Based Compensation | 3.73M | 2.16M | 2.24M | 2.63M | 2.92M | 5.68M | 10.02M | 20.38M | 32.37M | 50.72M |
| Deferred Taxes | 6.9M | -1.3M | -1.47M | 646K | -133K | -285K | 58K | -44K | -292K | -8.86M |
| Other Non-Cash Items | -63K | -63K | 11K | -4.11M | 223K | 766K | 1.05M | 5.66M | -4.19M | 2.81M |
| Working Capital Changes | -13.96M | 1.77M | 556K | 30K | 33.52M | -26.09M | -2.65M | -676K | 5.63M | 5.71M |
| Change in Receivables | -107K | 121K | -232K | 175K | -653K | -1.03M | -459K | 1.76M | 130K | -614K |
| Change in Inventory | 0 | 571K | 613K | -783K | -4.54M | -2.02M | -2.97M | 0 | 0 | 0 |
| Change in Payables | 80K | 547K | -3K | 783K | 4.54M | 2.02M | 2.97M | 8.06M | 3.93M | 8.53M |
| Cash from Investing | 10.19M | -47.84M | 24.29M | -28.99M | -66.29M | -16.82M | -246.77M | -296M | -117.17M | 165M |
| Capital Expenditures | -551K | -279K | -315K | -507K | -1.24M | -2.64M | -2.05M | -2.89M | -5.62M | -3.08M |
| CapEx % of Revenue | 0.04% | 0.15% | 1.01% | - | 0.18% | 0.08% | 0.11% | 0.31% | - | - |
| Acquisitions | - | - | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 10.74M | -47.56M | 52.62M | 48.52M | 75.44M | 214.71M | 144.75M | -296M | 0 | 0 |
| Cash from Financing | 278K | 23.96M | 7.07M | 111.59M | 27.52M | 85.8M | 447.54M | 278.47M | 353.52M | 12.13M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - | - | - |
| Other Financing | 0 | 132K | 177K | 288K | 122K | 82K | 260K | 705K | 35K | 47K |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | -18.65M | -19.85M | -29.04M | -35.23M | -5.87M | -50.76M | -71.55M | -101.32M | -150.94M | -184.46M |
| FCF Margin % | -1.2% | -11.01% | -93.38% | - | -0.86% | -1.58% | -3.88% | -10.74% | - | - |
| FCF Growth % | -13.77% | -0.06% | -0.46% | -0.21% | 0.83% | -7.64% | -0.41% | -0.42% | -0.49% | -0.22% |
| FCF per Share | -1.31 | -1.28 | -1.61 | -1.81 | -0.23 | -1.47 | -1.64 | -1.67 | -2.26 | -2.37 |
| FCF Conversion (FCF/Net Income) | 1.15x | 0.85x | 0.94x | 1.01x | 0.11x | 1.67x | 0.88x | 0.79x | 0.80x | 0.77x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -23.54% | -36.81% | -61.51% | -49.55% | -42.6% | -21.9% | -21.87% | -19.72% | -22.12% | -27.85% |
| Return on Invested Capital (ROIC) | -447.75% | -75.68% | -70.76% | -78.32% | -47.85% | -22.01% | -23.13% | -18.32% | -21.92% | -29.68% |
| Gross Margin | 82.27% | 38.21% | -8122.83% | - | 100% | 100% | 100% | 100% | - | - |
| Net Margin | -101.12% | -1275.49% | -9872.67% | - | -609.09% | -89.65% | -427.85% | -1328.95% | - | - |
| Debt / Equity | - | - | 0.19x | 0.15x | 0.18x | 0.02x | 0.02x | 0.01x | 0.01x | 0.01x |
| Interest Coverage | - | - | - | -27.27x | -29.86x | -64.67x | - | - | - | - |
| FCF Conversion | 1.15x | 0.85x | 0.94x | 1.01x | 0.11x | 1.67x | 0.88x | 0.79x | 0.80x | 0.77x |
| Revenue Growth | -45.09% | -88.43% | -82.75% | -100% | - | 371.02% | -42.68% | -48.83% | -100% | - |
| 2020 | 2021 | 2022 | |
|---|---|---|---|
| License and Service | - | - | 9.43M |
| License and Service Growth | - | - | - |
| License And Service | 32.17M | 18.44M | - |
| License And Service Growth | - | -42.68% | - |
Xenon Pharmaceuticals Inc. (XENE) reported $7.5M in revenue for fiscal year 2024. This represents a 48% decrease from $14.3M in 2012.
Xenon Pharmaceuticals Inc. (XENE) grew revenue by 0.0% over the past year. Growth has been modest.
Xenon Pharmaceuticals Inc. (XENE) reported a net loss of $306.3M for fiscal year 2024.
Xenon Pharmaceuticals Inc. (XENE) has a return on equity (ROE) of -27.8%. Negative ROE indicates the company is unprofitable.
Xenon Pharmaceuticals Inc. (XENE) had negative free cash flow of $253.3M in fiscal year 2024, likely due to heavy capital investments.